Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irx4204
- Development stage
- Phase 2
- Lead developer
- Io Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IRX4204 is an orally bioavailable, highly selective, and potent second-generation agonist of the retinoid X receptor (RXR), also known as a rexinoid. It activates RXR homodimers and RXR/Nurr1 heterodimers at nanomolar concentrations without significant activity on other nuclear receptors. The drug exhibits antineoplastic, neuroprotective, immunoregulatory, and disease-modifying activities. Preclinical studies have shown that IRX4204 promotes survival of dopaminergic neurons and supports myelin repair. Clinically, IRX4204 has been evaluated in phase I/II trials for various cancers and Parkinson’s disease and has demonstrated safety with long-term oral dosing. It is being developed by Io Therapeutics. Ongoing development includes planned phase II trials for amyotrophic lateral sclerosis (ALS) and consideration for Alzheimer’s disease.
- Other names
- retinoid X receptor agonist IRX4204rexinoid IRX4204
02
Targets
RXRA (Retinoid X receptor alpha)RXRB (Retinoid X receptor beta)RXRG (RXRγ)NR4A2 (Nuclear receptor subfamily 4 group A member 2)
Beyond the preview
Go deeper on irx4204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irx4204.